# Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

> **NCT02332590** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 369 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Sarilumab
- **DRUG:** Adalimumab
- **DRUG:** Placebo (for sarilumab)
- **DRUG:** Placebo (for adalimumab)

## Key facts

- **NCT ID:** NCT02332590
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-28
- **Primary completion:** 2016-01-20
- **Final completion:** 2020-12-29
- **Target enrollment:** 369 (ACTUAL)
- **Last updated:** 2022-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02332590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02332590, "Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02332590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*